AA amyloidosis as an adverse event of immune checkpoint inhibitor therapy: evidence from the FDA adverse event reporting system and a systematic review
Findings support AA amyloidosis as a rare but serious irAE of ICI therapy, warranting further investigation.
Authors
- Buğra Han Esen (ORCID: https://orcid.org/0000-0001-7430-1381)
- Mehmet Kanbay (ORCID: https://orcid.org/0000-0002-1297-0675)
- Şevval Nur Bektaş (ORCID: https://orcid.org/0000-0002-6953-3804)
- Fatih Selçukbırıcık (ORCID: https://orcid.org/0000-0002-1273-1674)
- A. Umur Topçu (ORCID: https://orcid.org/0000-0001-7286-3794)
Institutions
- Koç University (TR)
- Kochi Medical School Hospital (JP)
Publication Details
- Journal
- Amyloid
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1080/13506129.2025.2589197
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00